Cleveland-based U: The Mind Company began accepting orders on March 18 for a $350 brain stimulation headset marketed for cognitive enhancement and wellness. The device uses what the company calls am-tPRNS, or amplitude-modulated transcranial pulsed random noise stimulation. Orders placed now will receive an alpha prototype within one to three months, with an upgraded model promised within six to twelve months at no extra cost.
The company’s marketing materials cite striking numbers: a 67 percent reduction in tremor amplitude in a Parkinson’s study and a 580 percent increase in hippocampal activation in an Alzheimer’s study. These claims warrant scrutiny. Neither study appears in peer-reviewed literature, PubMed, or any conference proceedings that can be independently located. The numbers originate from a single press release and the company’s own website. No journal citations, sample sizes, or methodological details have been made public for either figure.
What is verified
U: The Mind Company does have a registered Phase 1/2 clinical trial (NCT07182058) for Parkinson’s disease on ClinicalTrials.gov. The trial uses a device called Sphere V3.0, delivering up to 4 milliamps through a four-electrode array targeting the motor cortex. The protocol calls for 13-minute daily sessions, five days a week for three weeks, followed by a three-week follow-up without the device. The trial is currently recruiting and is conducted remotely via telehealth.
The company also claims 225 trial subjects and 25,000 hours of safety data across two completed pilot studies. These pilots have not been published in peer-reviewed form.
The team includes credentialed individuals. Board member Dr. David Mishelevich holds an M.D. and Ph.D. in biomedical engineering from Johns Hopkins, has 20 patents in neuromodulation, and chaired the first Department of Medical Computer Science in the United States at UT Southwestern. Chairman Jeff Spitzner completed postdoctoral research at MIT. Founder Mohammed Abouelsoud studied computational neuroscience and applied physics at Ohio State.
The regulatory gap
The device is sold explicitly as a wellness and cognitive optimization product, not a medical device. The company’s own website includes the disclaimer: “INVESTIGATIONAL DEVICE, LIMITED BY UNITED STATES LAW TO INVESTIGATIONAL USE. The Medical Device is not cleared by the FDA for commercial distribution in the United States.”
This creates a two-track strategy that is increasingly common in consumer neurotech. The wellness product ships now with no FDA oversight. The medical device, targeting Parkinson’s and Alzheimer’s indications, is on a separate track with FDA submissions planned for 2027. In the meantime, marketing materials reference clinical outcomes from the medical research programme to sell the consumer product.
The underlying technology, transcranial random noise stimulation (tRNS), does have a published evidence base. Studies in the Journal of Neuroscience and Scientific Reports have shown effects on cortical excitability and motor learning. But the specific “am-tPRNS” protocol is proprietary to U: The Mind Company and does not appear in the independent scientific literature under that name. Whether the company’s waveform represents a meaningful advance over standard tRNS, or a marketing distinction, cannot be assessed without published data.
Context: what FDA-approved looks like
The timing of this launch is notable because the FDA approved Flow Neuroscience’s FL-100 headset for at-home depression treatment just three months earlier, in December 2025. Flow went through the PMA pathway, the agency’s most demanding review process. It was backed by a 174-person randomized controlled trial published in Nature Medicine showing a 44.9 percent remission rate. The FL-100 costs $500 to $800 and requires a prescription.
The contrast is instructive. Flow spent years in clinical development, secured a CE Mark in 2019, accumulated tens of thousands of European users, and then navigated a Class III FDA review. U: The Mind Company is selling a device at half the price with no FDA clearance, citing clinical data that has not been independently published.
That does not necessarily mean the device is ineffective. It means the evidence is not yet available for anyone outside the company to evaluate. The registered Parkinson’s trial on ClinicalTrials.gov is a legitimate step toward generating that evidence. But the consumer product is already on sale, and the claims being used to market it outpace what has been publicly demonstrated.
The bigger picture
Consumer brain stimulation is a growing market with minimal regulatory guardrails. A 2016 analysis in the Annals of Neurology noted the absence of meaningful FDA oversight for consumer transcranial stimulation devices. A 2022 study in PLOS Biology raised questions about whether current from external devices reliably reaches the brain at therapeutic levels, noting that some observed effects may be placebo-driven.
For the neurotech sector, devices like this present a familiar tension. Consumer interest drives awareness and investment. But unsubstantiated claims, if they do not hold up, risk poisoning public trust in a technology category that includes legitimate, life-changing clinical tools.